LENZ Therapeutics (LENZ) Net Cash Flow (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Net Cash Flow for 4 consecutive years, with -$220000.0 as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 98.95% to -$220000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, up 133.0% year-over-year, with the annual reading at $4.9 million for FY2025, 133.0% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$220000.0 at LENZ Therapeutics, up from -$12.3 million in the prior quarter.
  • The five-year high for Net Cash Flow was $165.3 million in Q1 2024, with the low at -$191.9 million in Q1 2022.
  • Average Net Cash Flow over 4 years is -$20.7 million, with a median of -$12.3 million recorded in 2025.
  • The sharpest move saw Net Cash Flow skyrocketed 136.67% in 2023, then plummeted 98.26% in 2025.
  • Over 4 years, Net Cash Flow stood at -$8.7 million in 2022, then surged by 912.55% to $70.4 million in 2023, then tumbled by 129.68% to -$20.9 million in 2024, then skyrocketed by 98.95% to -$220000.0 in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$220000.0, -$12.3 million, and $14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.